Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

VBI hep B vaccine meets late-stage study’s main goals

VBI Vaccines Inc. said a late-stage study testing the company’s hepatitis B vaccine against GlaxoSmithKline’s Engerix-B met the main goals.

Read More »

Global Blood Therapeutics’ Sickle Cell Disease Drug Hits the Mark in Phase III Trial

Global Blood Therapeutics reported new data from the company’s Phase III HOPE trial of voxelotor in sickle cell disease (SCD).

Read More »

Novartis’ Cosentyx Reaps Positive Results in Psoriatic Arthritis Trial

Novartis released positive data from the company’s FUTURE 5 clinical trial of Cosentyx (secukinumab) in psoriatic arthritis.

Read More »

Experimental drug delays type 1 diabetes onset in mid-stage trial

In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more.

Read More »

Astex Pharma and Otsuka’s Cancer Trial Meets Primary Endpoints

Astex Pharmaceuticals and Otsuka Pharmaceutical announced that the companies’ ASCERTAIN Phase III clinical trial of cedazuridine and decitabine (ASTX727) compared to decitabine IV alone hit the study’s primary endpoints.

Read More »

AstraZeneca’s blood cancer drug meets main goal in late-stage trial

AstraZeneca Plc’s blood cancer drug Calquence met the main goal of a final-stage study.

Read More »

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co. Ltd. will discontinue a late-stage study testing the company’s experimental treatment for amyloidosis, which did not meet the first of two main goals.

Read More »

Rare Cancer Treatments and the Power of Checkpoint Inhibitors Among Hot Topics at ASCO

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.

Read More »

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal

Camurus announced that the leading drug dependence journal Addiction published full results from a 48-week, open-label, global Phase 3 study of weekly and monthly Buvidal (prolonged-release buprenorphine), the first long-acting injection medicine to be approved for the treatment of opioid dependence in the EU and Australia.

Read More »

Without older subjects, cancer drug trials rely on atypical patients

Cancer drug study patients tend to be younger than most people with the disease in the general population.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom